The Cooper Companies (COO) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
24 Feb, 2026Executive summary
Fiscal 2025 featured organizational transformation, exceeding earnings expectations each quarter, double-digit earnings growth, and outperformance in free cash flow, with revenue reaching $4.09B, up 5% from 2024.
Gross margin was 66% (non-GAAP: 68%), operating margin 17% (non-GAAP: 26%), and free cash flow totaled $434M.
Nearly $300M of stock was repurchased, and the buyback program was expanded to $2B, with $1B remaining for future repurchases.
Major restructuring and integration activities were completed, unlocking $50M in expected annual pre-tax savings starting fiscal 2026.
Priorities for 2026 include accelerating growth, improving profitability, increasing cash generation, and continuing capital returns.
Voting matters and shareholder proposals
Shareholders will vote to elect nine directors for one-year terms, ratify KPMG LLP as independent auditor for FY2026, and approve executive compensation on an advisory basis.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
Board consists of nine nominees, 89% independent, 57% female, with an average age of 67 and median tenure of 4.7 years.
All committees (Audit, Corporate Governance & Nominating, Organization & Compensation) are composed of independent directors.
Board and committee self-evaluations are conducted annually, with third-party facilitation.
Directors are subject to stock ownership requirements and annual elections.
Board refreshment is ongoing, with six of nine directors joining in the past five years.
Latest events from The Cooper Companies
- Q1 2026 saw 6% revenue growth, raised FY26 guidance, and strong cash flow and share buybacks.COO
Q1 20266 Mar 2026 - Key votes include director elections, auditor ratification, and executive pay approval.COO
Proxy Filing24 Feb 2026 - Contact lens growth accelerates on capacity gains and premium demand, with margins set to improve.COO
Jefferies Global Healthcare Conference1 Feb 2026 - FY24 guidance raised as growth, innovation, and market leadership drive a positive outlook.COO
The 44th Annual William Blair Growth Stock Conference1 Feb 2026 - Q3 revenue up 8% to $1.0B, net income up 23%, and full-year guidance raised.COO
Q3 202423 Jan 2026 - Double-digit growth, margin gains, and strong guidance highlight sustained momentum.COO
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Growth in vision and fertility, innovation in myopia control, and focus on free cash flow.COO
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - FY26 guidance, innovation, and strategic review support growth in expanding healthcare markets.COO
44th Annual J.P. Morgan Healthcare Conference15 Jan 2026 - Record revenues, margin expansion, and strong 2025 growth outlook despite headwinds.COO
Q4 202411 Jan 2026